Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results

Yüce Kahraman Ç., Sincan G., Tatar A.

EURASIAN JOURNAL OF MEDICINE, cilt.54, sa.2, ss.181-185, 2022 (ESCI) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 54 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5152/eurasianjmed.2022.21102
  • Dergi Adı: EURASIAN JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.181-185
  • Anahtar Kelimeler: Myeloid, malignancies, NGS, panel testing, myeloid panel testing, POLYCYTHEMIA-VERA, MUTATION, DIAGNOSIS, BIOLOGY, AML
  • Atatürk Üniversitesi Adresli: Evet

Özet

Objective: Myeloid malignancies are heterogeneous disorders due to defective hematopoiesis and myeloid differentiation of hematopoietic stem/progenitor cell. The molecular landscape of the diseases is complex. Molecular alterations are used for classification and evaluation of prognosis and treatment. We aimed to evaluate the advantages of the next-generation sequencing panel testing in myeloid malignancies and clinical outcomes.